LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIAL

被引：0
|
作者：
Wang, Y. [1 ]
Chang, Y. -J. [1 ]
Huang, X. -J. [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1517
引用
收藏
页码：618 / 619
页数：2
相关论文
共 50 条
  • [21] Phase III prospective randomized trial of FPO with or without G-CSF versus supportive therapy alone in the treatment of Myelodysplastic syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).
    Miller, KB
    Kim, HT
    Greenberg, P
    van der Jagt, R
    Bennett, JM
    Tallman, MS
    Paietta, E
    Dewald, G
    Houston, JG
    Thomas, M
    Rowe, J
    BLOOD, 2004, 104 (11) : 24A - 24A
  • [22] Low-dose interleukin-2 plus G-CSF/EPO administration early after autologous PBSC transplantation -: Results of a prospective study in women with breast and ovarian cancer
    Perillo, A
    Pierelli, L
    Battaglia, A
    Salerno, MG
    Cortesi, E
    Fattorossi, A
    De Rosa, L
    Ferraù, F
    Ludovisi, M
    Leone, G
    Mancuso, S
    Scambia, G
    BONE MARROW TRANSPLANTATION, 2002, 29 : S194 - S194
  • [23] Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides
    Rupoli, Serena
    Canafoglia, Lucia
    Goteri, Gaia
    Leoni, Pietro
    Brandozzi, Giuliano
    Federici, Irene
    Micucci, Giorgia
    Giantomassi, Federica
    Mozzicafreddo, Giorgio
    Alterini, Renato
    Filosa, Giorgio
    Ricotti, Giuseppe
    Simonacci, Marco
    Scortechini, Anna Rita
    Zizzi, Antonio
    Pimpinelli, Nicola
    EUROPEAN JOURNAL OF DERMATOLOGY, 2016, 26 (01) : 13 - 20
  • [24] Overall Survival Results from a Prospective, Multicenter Phase II Trial of Low-Dose Erlotinib as Maintenance in NSCLC Harboring EGFR Mutation
    Hirano, S.
    Naka, G.
    Takeda, Y.
    Iikura, M.
    Hiroishi, T.
    Shikano, K.
    Yanagisawa, A.
    Hayama, N.
    Fujita, T.
    Amano, H.
    Nakamura, M.
    Nakamura, S.
    Tabeta, H.
    Sugiyama, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2128 - S2128
  • [25] Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors
    Young, Scott D.
    Whissell, Mark
    Noble, Jonathan C. S.
    Cano, Pablo O.
    Lopez, Pedro G.
    Germond, Colin J.
    CLINICAL CANCER RESEARCH, 2006, 12 (10) : 3092 - 3098
  • [26] Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides
    Serena Rupoli
    Lucia Canafoglia
    Gaia Goteri
    Pietro Leoni
    Giuliano Brandozzi
    Irene Federici
    Giorgia Micucci
    Federica Giantomassi
    Giorgio Mozzicafreddo
    Renato Alterini
    Giorgio Filosa
    Giuseppe Ricotti
    Marco Simonacci
    Anna Rita Scortechini
    Antonio Zizzi
    Nicola Pimpinelli
    European Journal of Dermatology, 2016, 26 : 13 - 20
  • [27] Use of G-CSF in patients with severe aplastic anaemia treated with ATG and cyclosporine increases neutrophils and decreases infection rates and hospitalization days but does not improve long-term outcome: Results of a prospective randomized clinical trial
    Tichelli, A.
    Schrezenmeier, H.
    Socie, G.
    Marsh, J.
    Bacigalupo, A.
    Duehrsen, U.
    Franzke, A.
    Hallek, M.
    Thiel, E.
    Wilhelm, M.
    Hoechsmann, B.
    Barrois, A.
    Champion, K.
    Passweg, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S31 - S31
  • [28] Phase II clinical study of rituximab and high-dose biweekly THP-COP (pirarubicin, cyclophosphamide, vincristine and predonisolone) with G-CSF for non-Hodgkin lymphoma: Results of a multicentric study of NMLSG (Niigata Malignant Lymphoma Study Group).
    Takizawa, J
    Aoki, S
    Takai, K
    Kurasaki, T
    Honma, K
    Higashimura, M
    Nagai, K
    Momoi, A
    Nikkuni, K
    Aizawa, Y
    BLOOD, 2005, 106 (11) : 264B - 264B
  • [29] Preliminary results of AIDS clinical trials group (ACTG) study #149: Phase II trial of ABVD chemotherapy with G-CSF in HIV infected patients with Hodgkin's Disease (HD)
    Levine, AM
    Cheung, T
    Tulpule, A
    Huang, J
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (04): : S7 - S7
  • [30] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
12345